Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Givosiran: Elevations in Blood Homocysteine

Standard response letter on givosiran and elevations in blood homocysteine.

Patisiran Global Open-Label Extension Study at 36 Months: Effect of Long-Term Treatment on Mortality and Ambulatory Function in Patients with hATTR Amyloidosis with Polyneuropathy

HELIOS-A: 9-Month Results from the Randomized Treatment Extension Period of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Patisiran: Temperature Excursions

Standard response letter on patisiran and temperature excursions. The letter includes information on the impact of temperature excursions not lower than -4°C and up to 40°C on the stability of patisiran.

Zilebesiran: KARDIA-1 Study

Standard response letter on zilebesiran and the KARDIA-1 study, an ongoing phase 2 study evaluating the efficacy and safety of zilebesiran dosing regimens for adults with mild to moderate hypertension.

Patisiran: Observation Period After Infusion

Standard Response Letter on the observational period after patisiran infusion in the APOLLO, APOLLO-B, Global OLE, and HELIOS‑A studies.

Patisiran: Dose Ranging Studies

Standard response letter on patisiran phase 1 and phase 2 dose ranging studies.

Vutrisiran: Use in Patients with Heart Transplant

Standard response letter on the use of vutrisiran in patients who have received a heart transplant.

Vutrisiran: Pain in Extremity

Standard response letter on vutrisiran and the adverse event of pain in extremity.

Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with Hereditary Transthyretin Mediated (hATTR) Amyloidosis with a V122I or T60A Variant: A Phase 4 Observational Study

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.